Application of BTK inhibitor in preparation of medicine for treating retinal neovascularization

By inhibiting the inflammatory activity of retinal microglia and macrophages through BTK inhibitors, combined with anti-VEGF drugs, the infection risk and side effects of retinal neovascularization treatment in the prior art were solved, and more efficient treatment effects were achieved. Pathological neovascularization provides new treatment options.

CN118987215APending Publication Date: 2024-11-22TIANJIN MEDICAL UNIVERSITY GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410965183.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Among the existing retinal pathological neovascular treatment methods, repeated injection of anti-VEGF drugs leads to the risk of intraocular infection and side effects, and lacks drugs that inhibit the inflammatory activity of myeloid cells as a treatment mechanism, and the clinical treatment effect is poor.

Method used

BTK inhibitors such as acatinib, obutinib, and Fenebrutinib are used to reduce neovascularization by inhibiting the inflammatory activity of retinal microglia and macrophages, and are used in combination with anti-VEGF drugs to improve the therapeutic effect.

Benefits of technology

Effectively reduce the formation of retinal neovascularization, provide new therapeutic targets and methods, improve traditional treatment effects, and provide more efficient treatment plans for diseases such as diabetic retinopathy and age-related macular degeneration, with safety and effect. better.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987215A_ABST
    Figure CN118987215A_ABST
Patent Text Reader

Abstract

The invention provides an application of a BTK inhibitor in preparation of a medicine for treating retinal neovascularization. The BTK inhibitor is acatinib. The BTK inhibitor reduces the formation of new vessels by inhibiting retina microglial cells and / or macrophages. The effect of the BTK inhibitor in treatment of retinal neovascularization is confirmed for the first time, a new target spot and a novel treatment mode for reducing fundus neovascularization by inhibiting the inflammatory activity of retinal myeloid cells are created, new application of the medicine is increased, the treatment effect of the traditional intravitreal injection anti-VEGF medicine is particularly improved, and the application of the BTK inhibitor in treatment of retinal neovascularization is promoted. And a safe and effective new choice is provided for treatment modes and drug combination of fundus neovascularization diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and in particular relates to the application of BTK inhibitors in the preparation of drugs for treating retinal neovascularization. Background Art

[0002] At present, the treatment of retinal pathological neovascularization is mainly through intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs. The risk of intraocular infection and side effects caused by repeated injections, as well as the lack of response or drug resistance after long-term treatment, are always urgent clinical problems to be solved. It is necessary to find the mechanism of action of drugs that inhibit other pro-angiogenic factors or pro-inflammatory mediators to treat retinal neovascularization as soon as possible. On the other hand, the role of the combined use of anti-angiogenic therapy and immunotherapy in pathological retinal angiogenesis is not clear, and there is currently no drug in clinical practice to treat retinal pathological neovascularization by inhibiting the inflammatory activity of myeloid cells. Summary of the invention

[0003] In view of this, the present invention aims to overcome the defects in the prior art and proposes the use of BTK inhibitors as drugs for the preparation of drugs for treating retinal neovascularization.

[0004] To achieve the above object, the technical solution of the present invention is achieved as follows:

[0005] The present invention provides a BTK inhibitor for use in preparing a drug for treating retinal neovascularization. The BTK inhibitor is at least one of acalabrutinib, orelabrutinib, and fenebrutinib.

[0006] Furthermore, the BTK inhibitor reduces the formation of new blood vessels by inhibiting retinal microglia and / or macrophages.

[0007] Furthermore, the BTK inhibitor reduces angiogenesis of retinal vascular endothelial cells by inhibiting the activation of inflammasomes in microglia and / or macrophages.

[0008] Furthermore, the retinal neovascularization includes one of proliferative diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration; and the retinal neovascularization is pathological retinal neovascularization.

[0009] Furthermore, the BTK inhibitor inhibits the expression of pro-inflammatory factors; the BTK inhibitor promotes the expression of anti-inflammatory factors.

[0010] Furthermore, the pro-inflammatory factor is at least one of IL-1β, IL-6 or TNF-α.

[0011] Furthermore, the anti-inflammatory factor is at least one of IL-10 and TGF-β.

[0012] The present invention also provides a retinal neovascularization inhibitory composition, comprising a BTK inhibitor and an anti-VEGF drug in a mass ratio of 4:1-1:2.

[0013] Furthermore, the BTK inhibitor is at least one of acalabrutinib, orelabrutinib, and fenebrutinib; and the anti-VEGF drug is conbercept.

[0014] The present invention also provides a medicine for treating retinal neovascularization, which comprises the BTK inhibitor or the composition.

[0015] Furthermore, the administration method of the drug includes oral administration or intraocular injection.

[0016] Preferably, the drug is administered by intravitreal injection.

[0017] Compared with the prior art, the present invention has the following advantages:

[0018] The present invention confirms for the first time the role of BTK inhibitors in the treatment of retinal neovascularization, and creates a new target and new treatment method for reducing fundus neovascularization by inhibiting the inflammatory activity of retinal myeloid cells, adding new uses for drugs, especially improving the therapeutic effect of traditional intravitreal injection of anti-VEGF drugs, and providing a safe and effective new choice for the treatment of fundus neovascularization diseases and combined medication. The BTK inhibitor proposed in the present invention is used to treat retinal neovascularization, providing a more efficient treatment method for diseases such as diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The oxygen-induced retinopathy (OIR) mouse model described in Example 1 of the present invention is constructed: wherein, Figure A shows the mouse breeding conditions, Figure B shows the staining of the retinal vascular plexus of mice at P17, C shows the area of ​​new blood vessels, and D shows the area of ​​the avascular zone;

[0020] Figure 2 The retinal flat mount described in Example 2 of the present invention is used to detect the therapeutic effect by immunofluorescence staining: wherein, Figure A is retinal blood island formation, Figure B is an immunofluorescence image of retinal extravascular red blood cell leakage, Figure C is the percentage of red blood cell leakage, Figure D is FITC-labeled vascular leakage, and Figure E is the leakage percentage of FITC-Dextran;

[0021] Figure 3The mechanism verification of the BTK inhibitor in Example 3 of the present invention for treating retinal blood vessels: wherein, Figure A shows the administration time of PLX5622 for deleting microglia, Figure B shows the number of retinal microglia / macrophages, Figure C shows the corresponding percentage of new blood vessel area, and Figure D shows Rag1 - / - The BTK inhibitor administration process in mice, Figure E shows the corresponding percentage of neovascularization area;

[0022] Figure 4 The regulation of retinal inflammation and microglia / macrophages by the BTK inhibitor described in Example 4 of the present invention: wherein, Figure A shows the distribution of F4 / 80-positive macrophages in the retina, Figure B shows the number of F4 / 80-positive macrophages, Figure C shows the expression of IL-1β, IL-6, TNF-α, IL-10, and TGF-β, and Figures D-E show the expression of NLRP3, caspase-1, and IL-1β;

[0023] Figure 5 The effect of BTK inhibition on the branching morphology of microglia described in Example 4 of the present invention: wherein, Figure A is the cytoskeleton of a single microglia after staining, Figure B is a quantitative analysis of all synaptic structures of Iba-1-positive microglia, Figure C is the proportion of CD86-positive differentiation groups, Figure D is the proportion of CD206-positive differentiation groups, Figure E is the expression of IL-1β, IL-6, TNF-α, CCL2, CCL5, CX3CR1, CXCL10, iNOS, CD68, and CD86, and Figure F is the expression of IL-10, TGF-β, CD163, and CD206;

[0024] Figure 6 This is a test of the synergistic effect of the BTK inhibitor and the anti-VEGF drug described in Example 5 of the present invention: wherein, Figure A shows the administration time of Acalabrutinib and Conbercept, and Figure B shows the inhibitory effect of Acalabrutinib and Conbercept on retinal pathological neovascularization;

[0025] Figure 7 This is an in vitro verification that the BTK inhibitor described in Example 6 of the present invention reduces retinal angiogenesis by regulating microglial function: wherein, Figure A is a preventive medication experiment of cell scratches, Figure B is the migration ability of microglia after drug administration, Figure C is the corresponding microglial migration area statistics, Figure D is an intervention experiment of cell scratches, Figure E is the migration ability of microglia after drug administration, and Figure F is the corresponding microglial migration area statistics; Figure G is the expression of IL-1β, IL-6, and TNF-α, and Figures H-I are the expressions of NLRP3, caspase-1, and IL-1β;

[0026] Figure 8The direct effect of microglial BTK inhibition on retinal angiogenesis as described in Example 6 of the present invention: wherein, Figure A shows the co-culture process, Figures B-E show the changes in the proliferation and tube-forming ability of retinal vascular endothelial cells, and Figures F-G show the sprouting ability of human retinal microvascular endothelial cells (HRMEC);

[0027] Fig. 9 This is the evaluation of retinal safety described in Example 7 of the present invention: wherein Figure A is HE staining of retinal structure, and Figure B is retinal cell apoptosis detection. DETAILED DESCRIPTION

[0028] Unless otherwise defined, the technical terms used in the following examples have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. The test reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.

[0029] The present invention will be described in detail below with reference to the embodiments.

[0030] Example 1 Construction of oxygen-induced retinopathy (OIR) mouse model and therapeutic administration

[0031] Wild-type C57 / BL6J mice were housed in a sterile barrier of an SPF-grade animal laboratory in an environment with a constant temperature (22°C ± 1°C), relative humidity (50% ± 5%), and a 12 h:12 h light / dark cycle with free access to sterile feed and water.

[0032] Neonatal C57 / BL6J mice were exposed to 75% oxygen from P7 to P12 and then returned to a normal oxygen concentration environment for 5 days. During the treatment, the BTK inhibitor Acalabrutinib (10 mg / kg) was injected at P12, dissolved in 0.1% dimethyl sulfoxide (DMSO) and diluted with normal saline (0.9% NaCl).

[0033] The intravitreal injection used 5% isoflurane to anesthetize mice, compound tropicamide eye drops were used to dilate the mice for 5-10 minutes, and a micro-syringe and a 33-gauge bevel syringe needle were used to inject into the vitreous 1 mm behind the corneal limbus, and 1 μL of saline solution was injected into the vitreous cavity as a control or the same concentration of drugs. In order to prevent the injection solution from escaping from the eye after the needle was removed, the needle tip stayed in the eye for 30 seconds after the injection was completed, and the needle was pulled out after the drug was diffused. The sterile cotton swab was gently pressed and wiped dry. The conjunctival sac was coated with ofloxacin gel to prevent infection through local antibiotics. Newborn C57 / BL6J mice were placed in a 75% hyperoxia environment from P7 to P12 after birth, and then returned to a normal oxygen environment for 5 days. Hyperoxia leads to vascular occlusion, and normoxic environment leads to pathological neovascularization. At P12, the BTK inhibitor Acalabrutinib (Acalabrutinib) was administered or saline was injected as a control to observe whether BTK inhibition has an anti-angiogenic effect. Mice were sacrificed at P17 and ocular samples were collected as Figure 1 As shown in Figure A. The quantitative results of staining the retinal vascular plexus with Isolectin B4 (IsoB4) showed that the area of ​​retinal neovascularization in the mice injected with BTK inhibitor was significantly reduced compared with the control group. Figure 1 As shown in the BD figure.

[0034] Example 2 Immunofluorescence staining of retinal flat mounts to detect bleeding and leakage after treatment

[0035] The samples were collected at P17 and fixed in 4% paraformaldehyde (PFA) at 4°C for 1 hour. The retinas were dissected, washed with phosphate-buffered saline (PBS), permeabilized with PBS containing 1% TritonX-100 at 4°C for 12 hours, and then blocked in PBS containing 2% bovine serum albumin (BSA) and 0.3% TritonX-100 for 12 hours. To observe retinal blood vessels, after blocking, the retinas were stained with IsoB4 (1:100, Alexa Fluor 594-conjugated) for 2 hours at room temperature. For immunofluorescence staining of erythrocytes, macrophages, microglia, and BTK protein, retinal flat mounts were incubated with the following primary antibodies in blocking solution for 36 hours: rat anti-TER119 antibody (1:200); rabbit anti-F4 / 80 antibody (1:200); rabbit anti-Iba-1 antibody (1:200); mouse anti-CD86 antibody (1:100); mouse anti-CD206 antibody (1:100); rabbit anti-BTK antibody (1:200). After washing, incubation with the corresponding secondary antibody (1:300) was performed at room temperature for 2 hours. After washing in the dark, the retina was cut into four pieces with microscissors, flattened and placed on a slide with a drop of mounting medium, sealed with a coverslip, and dried in the dark. The whole retina was observed and photographed using a scanning laser confocal fluorescence microscope (LSM800, Carl Zeiss) equipped with a 20× Plan-Apochromat air objective with a numerical aperture of 0.8 and a 10× Plan-Apochromat air objective with a numerical aperture of 0.45. The images were processed using ZEISS Blue (ZEN) software. The neovascularization and avascular areas of the Isob4-stained retinal images were calculated using Photoshop software. The cytoskeleton and synaptic branch morphology of each Iba-1-stained microglia were determined by MotiQ 3D visualization analysis in ImageJ software.

[0036] The method of FITC-Dextran intracardiac perfusion is to find the most obvious apical beat of the mouse on the left side of the sternum on the axillary line, place a 31-gauge needle 2mm above the heart, and inject 50μl of PBS solution containing FITC-Dextran (25mg / mL, 70kDa) into the heart. Samples were collected after 10 minutes of circulation. Vascular leakage was measured by ImageJ software, that is, the area of ​​extravascular Dextran divided by the total retinal area.

[0037] Abnormal retinal blood vessel growth in the OIR model also leads to a certain degree of blood-retinal barrier (BRB) disruption. The preliminary results of the present invention showed that there was extensive retinal hemorrhage in the retina of OIR mice at P17, and the formation of retinal blood islands in the Acalabrutinib-treated group was significantly reduced, such as Figure 2As shown in Figure A. By counting the area of ​​erythrocytes leaking out of blood vessels, that is, in the immunofluorescence images of retinal flat mounts co-stained with IsoB4 and TER119 (a red blood cell marker), the results of counting the area of ​​TER119 positive staining and IsoB4 negative staining in the total retinal area further found that compared with the control group, BTK inhibitors significantly reduced the leakage of erythrocytes in the neovascularization area of ​​OIR mice, as shown in Figure 2. Figure 2 In addition, the present invention uses fluorescein isothiocyanate (FITC) labeled dextran (70 kDa) injected into the blood circulation to detect vascular leakage in the retina of OIR mice at P17. The results showed that compared with the control group, the BTK inhibitor treatment group had significantly less FITC-Dextran extravasation, as shown in FIG. Figure 2 As shown in the DE diagram.

[0038] Example 3 Verification of the mechanism of BTK inhibitors in treating retinal blood vessels

[0039] In order to eliminate microglia / macrophages in mice in vivo, we prepared PLX5622 (a specific inhibitor of colony stimulating factor 1 receptor CSF1R) injection with a final DMSO concentration of 2% to eliminate microglia / macrophages in OIR mice. From P7 to P17, the body weight of OIR mice was weighed every day, and PLX5622 was administered intraperitoneally for ten consecutive days at a dose of 40 mg / kg using an insulin needle after local skin disinfection. The mice were killed at P17 and eye specimens were collected. The changes in the therapeutic effect of BTK inhibitors after the elimination of microglia / macrophages were detected by immunofluorescence staining of retinal flat mounts.

[0040] In previous studies, PLX5622 was usually added to the daily feed for feeding, which is not suitable for newborn mice that rely on breast milk for feeding. Therefore, in the present invention, we used intraperitoneal injection to administer PLX5622 from P7 to P17 according to the weight of mice to remove retinal microglia / macrophages in the OIR retina. Figure 3 As shown in Figure A. The body weight of the mice in the drug-treated group and the control group was measured every day. It was found that the body weight growth rate of the mice in the continuous administration of PLX5622 treatment group was no different from that in the control group, which ruled out the effect of systemic administration of PLX5622 on mice. Through immunofluorescence images stained with IsoB4 and Iba-1 (microglia markers), we observed that PLX5622 effectively removed retinal microglia / macrophages, such as Figure 3 As shown in Figure B.

[0041] Compared with normal OIR mice, OIR mice with microglia removed had reduced retinal neovascularization, suggesting that microglia play a role in promoting pathological retinal angiogenesis. In addition, after microglia / macrophage removal, the inhibitory effect of Acalabrutinib on retinal neovascularization disappeared ( Figure 3 C), indicating that microglia / macrophages play an important role in the therapeutic process of reducing retinal neovascularization by BTK inhibition in OIR mice.

[0042] To further explore the role of lymphocytes in retinal neovascularization induced by BTK inhibitors, we used Rag1-deficient mature lymphocytes. - / - The mice were subjected to repeated OIR modeling and BTK inhibitor administration. Figure 3 As shown in Figure D. The results of quantification of IsoB4-stained retinal neovascularization showed that acalabrutinib injection had an inhibitory effect on Rag1 - / - The inhibitory effect on retinal neovascularization in mice was consistent with that in wild-type mice treated with Acalabrutinib, such as Figure 3 As shown in Figure E, BTK inhibitors can reduce retinal neovascularization in the absence of lymphocytes.

[0043] Example 4 Regulation of BTK Inhibitors on Retinal Inflammation and Microglia / Macrophages

[0044] Retinal tissues were collected at P17, RNA was extracted using TRIzol, and RNA concentration was measured using a spectrophotometer. RNA samples were reverse transcribed into complementary DNA (cDNA). TM Green Master Mix and Applied Biosystems QuantStudio 3 instrument were used for quantitative reverse transcription PCR (qRT-PCR), with GAPDH as a control, to detect the effects of BTK inhibitors on inflammatory factors in the retina.

[0045] BTK protein is highly expressed in retinal microglia / macrophages. After BTK is inhibited, the number of F4 / 80+ macrophages originally gathered around new blood vessels is significantly reduced, such as Figure 4 As shown in the AB diagram in the figure. Next, the present invention focuses on the regulatory effect of BTK inhibitors on inflammatory factors in the retina. We found that after the administration of Acalabrutinib, the expression of pro-inflammatory factors (IL-1β, IL-6, TNF-α) in the retina was downregulated, and the expression of anti-inflammatory factors (IL-10, TGF-β) was upregulated, as shown in Figure AB. Figure 4As shown in Figure C. These results indicate that inhibition of BTK can reduce retinal inflammatory responses in OIR mice and play an anti-inflammatory role in the treatment of pathological neovascularization.

[0046] The decreased expression of proinflammatory factors may be associated with decreased activity of upstream inflammasomes. BTK is a component of the NLRP3 inflammasome complex, and inhibition of BTK may reduce the activation of the NLRP3 inflammasome and the formation of its downstream factors. Therefore, we further detected NLRP3 pathway proteins in the retina with BTK inhibition by Western blotting. Retinal tissues or cells were dissolved in RIPA solution containing protease inhibitors. The lysates were centrifuged at 12000g for 10 minutes at 4°C, and the supernatant was collected. After the protein samples were placed in a 95°C metal bath for 10 minutes, equal amounts of proteins were electrophoresed on a 10-15% SDS-polyacrylamide gel and transferred to a PVDF membrane. The membrane was blocked with skim milk for 1 hour at room temperature to block nonspecific binding. The membrane was incubated overnight in the primary antibody diluent, and the corresponding secondary antibody was used to bind to the primary antibody. The ECL immunoblotting analysis system was used for detection, and the bands on the same blot were statistically compared, and quantitative analysis was performed using ImageJ software. The results showed that the expression of NLRP3 and its downstream caspase-1 and IL-1β was decreased, e.g. Figure 4 As shown in the DE diagram, BTK inhibitors exert anti-inflammatory effects on the retina by inhibiting the activation of the NLRP3 signaling pathway and reducing the expression of proinflammatory cytokines.

[0047] In order to detect whether BTK inhibition has an effect on the branching morphology of microglia, the present invention used Iba-1 to stain the retinal microglia of mice raised under a normoxic environment, and analyzed the cytoskeleton of individual microglia using the MotiQ 3D visualization function in the ImageJ software, such as Figure 5 As shown in Figure A. Quantitative analysis of the span volume, branches, connection points, tips, and branch lengths of all synaptic structures of each Iba-1-positive microglia revealed no significant differences in the morphology of microglia after administration of Acalabrutinib, as shown in Figure 2. Figure 5 As shown in Figure B.

[0048] Retinal microglia / macrophages differentiated into an active inflammatory state reached a peak at the onset of OIR and then gradually decreased. In order to study whether BTK inhibition changes the inflammatory state of retinal microglia / macrophages, the present invention performed retinal flat mounts on P17 OIR mice and used CD86 and CD206 co-stained with Iba-1 to mark the inflammatory activity (M1) and immunomodulatory activity (M2) of microglia / macrophages, respectively. After BTK was inhibited, the proportion of CD86-positive differentiated populations in Iba-1-positive microglia / macrophages was significantly reduced, while the proportion of CD206-positive differentiated populations in Iba-1-positive microglia / macrophages tended to increase, as shown in Figure 2. Figure 5 Similarly, the expression of genes associated with microglia / macrophage inflammatory activity (IL-1β, IL-6, TNF-α, CCL2, CCL5, CX3CR1, CXCL10, iNOS, CD68, CD86) in the retina was significantly reduced, as shown in Figures C and D. Figure 5 As shown in Figure E in , genes related to microglia / macrophage immunoregulatory activity (IL-10, TGF-β, CD163, CD206) showed an upward trend, but there was no statistical difference, such as Figure 5 These results indicate that inhibition of BTK can reduce the inflammatory activity of microglia / macrophages in P17 OIR retinas without significantly increasing the immunoregulatory activity of microglia / macrophages.

[0049] Example 5 Detection of synergistic effects between BTK inhibitors and anti-VEGF drugs

[0050] Conbercept (KH902), an anti-VEGF humanized recombinant fusion protein approved by the U.S. Food and Drug Administration (FDA), can inhibit the pathological formation of new blood vessels and improve ischemia and hypoxia. It is widely used in the clinical treatment of choroidal neovascularization (CNV) secondary to diabetic retinopathy (DR) and age-related macular degeneration (AMD). The above results have shown that BTK inhibitors reduce retinal neovascularization by inhibiting inflammation. Therefore, we co-administered Conbercept and Acalabrutinib by intravitreal injection at P12 to compare their different inhibitory effects on pathological retinal neovascularization. Figure 6As shown in Figure A. When injecting into the vitreous cavity, first mix the Acalabrutinib injection and the 10 mg / mL Conbercept intraocular injection stored at 4°C in the dark in a ratio of 4:1-1:2 and inject the drug. The synergistic therapeutic effect is observed by immunofluorescence staining of retinal flatbeds. We used IsoB4 to stain the retinal neovascularization of the control group, Acalabrutinib, Conbercept and combination groups and performed quantitative analysis. We found that in P17 OIR mice, the use of Acalabrutinib and Conbercept alone reduced retinal neovascularization, as shown in Figure 1. Figure 6 As shown in Figure B. It is worth noting that the combined use of these two drugs significantly increased the inhibitory effect of Conbercept monotherapy on retinal neovascularization, suggesting that BTK inhibitors and anti-VEGF drugs have synergistic therapeutic effects, such as Figure 6 As shown in Figure B, the therapeutic effect of anti-VEGF can be increased.

[0051] Example 6 In vitro validation of BTK inhibitors reducing retinal angiogenesis by regulating microglial function

[0052] Microglial motility is associated with proinflammatory responses. Therefore, in the present invention, to determine whether BTK inhibition can regulate lipopolysaccharide (LPS)-induced microglial migration, we first performed a cell scratch assay, pre-treating BV2 microglia with solvent or Acalabrutinib (0.5 μM) for 1 hour, and then treating with PBS or LPS (0.1 μg / mL) for 23 hours. The results showed that Acalabrutinib pretreatment prevented the increase in LPS-induced microglial migration compared with the solvent group, as shown in Figure 2. Figure 7 We also performed BTK inhibition on microglia 1 hour after LPS stimulation, and the results also showed that Acalabrutinib reversed the LPS-induced increase in microglial migration, as shown in Figure AC. Figure 7 As shown in Figure DF. Therefore, BTK inhibitors can reduce LPS-induced microglial migration.

[0053] After BTK inhibitor treatment, the expression of proinflammatory cytokines (IL-1β, IL-6, TNF-α) in LPS-induced BV2 microglia was downregulated, e.g. Figure 7 As shown in Figure G. The results of detecting the expression of NLRP3 inflammasome pathway proteins in BV2 microglia showed that the expression of NLRP3, caspase-1 and IL-1β in BTK-inhibited microglia was significantly reduced compared with the LPS-treated group, as shown in Figure 2. Figure 7As shown in the HI figure, BTK inhibitors can reduce the activation of the NLRP3 pathway and the expression of proinflammatory cytokines in microglia.

[0054] In addition, the proliferation and sprouting ability of retinal endothelial cells are crucial for the formation of the vascular network. Therefore, we performed a co-culture experiment of BV2 microglia and human retinal microvascular endothelial cells (HRMECs) to further explore the direct role of microglial BTK inhibition in retinal angiogenesis. In the co-culture experiment, BV2 cells were pretreated with solvent (0.1% DMSO), LPS (0.1μg / mL) or Acalabrutinib (0.5μM) for 1 hour and then cultured in drug-free complete medium for 12 hours. The supernatant was collected and centrifuged, filtered with a 0.22μm filter, and mixed with an equal volume of endothelial cell culture medium to form a conditioned medium (CM) for co-culture of HRMECs ( Figure 8 A).

[0055] Proliferation assays EdU-positive HRMECs were stained with the 488EdU Cell Proliferation Kit. HRMECs were first treated with EdU labeling reagent for 2 hours, fixed with 4% paraformaldehyde for 20 minutes, washed with 3% BSA, and permeabilized in PBS containing 0.5% Triton X-100 for 10 minutes. They were then incubated with Click-iT at room temperature in the dark for 30 minutes and stained with Hoechst 33342 for 15 minutes. Images were collected using a laser confocal fluorescence microscope and processed using Zeiss Blue software.

[0056] The HRMEC tube formation experiment uses Matrigel to detect the ability of endothelial cells to form tubes. Place 50 μL of Matrigel into a 96-well plate and incubate at 37°C in a 5% CO2 incubator for 40 minutes. 4 HRMECs were seeded in Matrigel and co-cultured with the supernatant of microglia from different pre-treatment groups. The tube formation of each group was observed under a microscope after 12 hours, and the length of the tube was measured using ImageJ software.

[0057] Microcarrier bead sprouting experiments used Cytodex 3 microbeads, which were coated with HRMEC cells and embedded in 2mg / mL fibrin gel in 24-well plates. The gel was composed of 2mg / mL fibrinogen combined with 0.625Units / mL thrombin and 0.15Units / mL aprotinin in PBS. HRMEC-coated microcarrier beads were cultured in endothelial cell culture medium and pre-stimulated microglial supernatant was added. After 48 hours, they were fixed with 4% paraformaldehyde for 30 minutes at room temperature and then blocked with 1% BSA and 0.2% TritonX-100 in PBS for 1 hour. Subsequently, they were incubated with FITC-phalloidin (1mg / mL) for 1 hour. Confocal images were obtained using a scanning laser confocal fluorescence microscope, and the sprout length was analyzed using ImageJ software.

[0058] The results of the above experiments showed that BTK inhibitor-treated microglial supernatant can reduce the proliferation, tube formation and sprouting ability of retinal endothelial cells. Compared with the LPS-CM group, the proliferation and tube formation of retinal vascular endothelial cells co-cultured with BTK-inhibited microglial supernatant (Acalabrutinib-CM) were reduced, such as Figure 8 The budding ability of HRMEC was also significantly reduced, as shown in the BE figure. Figure 8 As shown in Figure FG, it is shown that the inhibition of BTK in microglia and the regulation of their inflammatory function can directly act on retinal endothelial cells and reduce angiogenesis. Therefore, the anti-inflammatory and anti-angiogenic effects of BTK inhibitors on retinal endothelial cells can be superimposed with the therapeutic effects of anti-VEGF drugs on retinal neovascularization, which also explains the synergistic effect of BTK inhibitors and anti-VEGF drugs in our drug combination.

[0059] Example 7 Evaluation of retinal safety

[0060] Safety assessment was performed using mice grown under normoxic conditions. Hematoxylin-eosin (H&E) staining was used to detect the retinal thickness of each group of mice; eyeball samples were fixed with 4% PFA overnight at room temperature, embedded in paraffin, and sliced ​​to 5 μm thickness. The slices near the optic nerve were selected for staining. A one-step TUNEL apoptosis detection kit was used to detect apoptotic cells in the retina. After P17, the samples were fixed in 4% PFA for 1 hour, then transferred to 30% sucrose dissolved in PBS at 4°C overnight, embedded in OCT, and frozen at -80°C. The slices near the optic nerve were selected, washed 3 times in PBS, and incubated in 3% BSA, 0.3% Triton X-100PBS at room temperature for 5 minutes. Then, the equilibration buffer containing nucleotide terminal deoxyribonucleotidyl transferase (TdT) was placed in a 37°C incubator to avoid light for staining for 1 hour, the cell nuclei were stained with DAPI and the slices were sealed, and the images were taken with a laser confocal fluorescence microscope, and the images were processed with Zeiss Blue software.

[0061] The results showed that there was no statistically significant difference in the thickness of the inner retinal layer (INL) and outer nuclear layer (ONL) between the control group and the Acalabrutinib-treated group. Fig. 9 As shown in Figure A. TUNEL staining for detecting cell apoptosis also showed that after the injection of Acalabrutinib, retinal cell apoptosis did not increase. Fig. 9 As shown in Figure B, the safety of intraocular administration of BTK inhibitors on the retina is demonstrated.

[0062] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A BTK inhibitor for use in the preparation of a drug for treating retinal neovascularization, characterized in that: The BTK inhibitor is at least one of acalabrutinib, orelabrutinib, and fenebrutinib.

2. The use according to claim 1, characterized in that: The BTK inhibitor reduces the formation of new blood vessels by inhibiting retinal microglia and / or macrophages.

3. The use according to claim 2, characterized in that: The BTK inhibitor reduces angiogenesis of retinal vascular endothelial cells by inhibiting the activation of inflammasomes of microglia and / or macrophages.

4. The use according to claim 1, characterized in that: The retinal neovascularization includes one of proliferative diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration; the retinal neovascularization is pathological retinal neovascularization.

5. The use according to claim 1, characterized in that: The BTK inhibitor inhibits the expression of pro-inflammatory factors; the BTK inhibitor promotes the expression of anti-inflammatory factors.

6. The use according to claim 5, characterized in that: The pro-inflammatory factor is at least one of IL-1β, IL-6 or TNF-α; the anti-inflammatory factor is at least one of IL-10 or TGF-β.

7. A composition for inhibiting retinal neovascularization, characterized in that: It includes BTK inhibitors and anti-VEGF drugs in a mass ratio of 4:1-1:

2.

8. The retinal neovascularization inhibitory composition according to claim 7, characterized in that: The BTK inhibitor is at least one of acalabrutinib, orelabrutinib, and fenebrutinib; the anti-VEGF drug is conbercept.

9. A drug for treating retinal neovascularization, characterized in that: The drug comprises the BTK inhibitor according to any one of claims 1 to 6 or the composition according to claim 7 or 8.

10. The drug according to claim 9, characterized in that: The administration of the drug includes oral administration or intraocular injection.